Local Surgeon Among First to Use New Intraocular Lens for Cataract Patients With and Without Presbyopia
Revolutionary Apodized Diffractive Technology Provides a High Level of Freedom from Glasses
Vero Beach, FL - June 9, 2005 - A revolutionary advance in cataract surgery will be introduced this month by Val Zudans, M.D. of the Florida Eye Institute in Vero Beach. AcrySof ReSTOR® IOL is the first and only apodized diffractive intraocular lens (IOL) for cataract patients with and without presbyopia. The AcrySof ReSTOR IOL, from Alcon, Inc., provides patients with a full range of quality vision (near, intermediate and distance), and greatly reduces reliance on glasses. In clinical trials, 80 percent of patients reported never wearing reading glasses or bifocals following bilateral cataract surgery.
The vast majority of patients who undergo cataract surgery today receive monofocal lenses, which typically require them to use reading glasses or bifocals for near vision following surgery. "With the new AcrySof ReSTOR IOL, patients have the potential to reduce their reliance on glasses," said Dr. Zudans. "This new lens is a breakthrough in cataract surgery that we are proud to offer our patients."
AcrySof ReSTOR is a foldable IOL and represents breakthrough technology because of its unique, patented optic design, which allows patients to experience the highest level of freedom from glasses ever achieved in IOL clinical trials. The AcrySof ReSTOR IOL uses a combination of three complementary technologies: apodization, diffraction and refraction, to allow patients to experience a full range of high-quality vision without the need for reading glasses or bifocals. This range of vision is achieved without glasses through the optical properties of the IOL. The end benefit for patients is an increased range of quality vision that results in a high level of spectacle freedom. Alcon patented the application of apodization technology to an IOL, making AcrySof ReSTOR the first and only apodized diffractive IOL.
The AcrySof ReSTOR IOL received approval by the U.S. Food and Drug Administration in March 2005. Clinical trials were conducted in the United States and Europe to establish the safety and effectiveness of the AcrySof ReSTOR IOL. A total of 566 patients received the AcrySof ReSTOR lens in clinical trials and had a mean age of 68 years.
Since its introduction outside the U.S. in 2003, more than 11,000 AcrySof ReSTOR IOLs have been implanted in patients by more than 1,000 surgeons in Europe and other countries. More than 500 ophthalmic surgeons outside of the U.S. have been trained to implant the AcrySof ReSTOR lens and thousands of lenses have already been successfully implanted.
A cataract is a "clouding" of the eye's natural lens, which results in blurred or defocused vision. According to a recent article published in the Archives of Ophthalmology, more than 20 million adults in the U.S. have developed cataracts making it the number one cause of poor vision in the United States. While not all cataracts require surgery, nearly 3 million cataract procedures are annually performed in the U.S. Cataracts cannot be prevented and are the leading cause of treatable blindness worldwide. According to the National Eye Institute, the number of Americans with cataracts is expected to rise to over 30 million people by the year 2020.
The Florida Eye Institute is among the first medical groups in the United States to receive the new lens.
About Val Zudans, M.D.
Dr. Zudans completed his ophthalmology residency at the Bascom Palmer Eye Institute at the University of Miami. He earned his undergraduate and medical degrees from the University of Florida. He performs no-needle, no-stitch, clear-cornea cataract surgery to minimize discomfort and speed recovery. He uses this same highly advanced procedure for ReSTOR presbyopia surgery. His additional expertise in refractive surgery such as LASIK, LASEK/PRK and AK allow him to further enhance the outcomes of cataract and ReSTOR procedures by correcting residual astigmatism, myopia, and hyperopia. Learn more about Dr. Zudans here.